Shots: The P-III EXPEDITION Study involves assessing of Solanezumab (400 mg, IV, q4w) vs PBO in 1,012 (EXPEDITION1) & 1,040 (EXPEDITION2) patients with mild or mild to moderate Alzheimer disease […]readmore
Tags : Lilly
Shots: • The NDA filling is based on results of P-III SAMURAI and SPARTAN study assessing Lasmiditan vs PBO in patients with migrane with or without aura in adults • […]readmore
Shots: Dicerna will receive $100M upfront plus ~$350M as development and commercialization milestones with tiered royalties and equity investment of $100M Lilly will get hold of Dicerna’s GalXC RNAi technology […]readmore
Shots: The P-III OA (A4091056) study involves evaluation of Tanezumab (2.5, 2.5/5 mg SC) vs PBO in 698 patients in ratio (1:1:1) with OA of the knee or hip for […]readmore
Shots: The two P-III trials i.e. COAST-V (N=341) & COAST-W (N=316) involves assessing of Taltz (80/160 mg, q4w/q2w) SC vs adalimumab, or PBO in patients with AS never undergone bDMARD […]readmore
Shots: The P-II study involves assessing of four doses of GIP/GLP-1 RA, LY3298176 (1 mg, 5 mg, 10 mg, 15 mg) vs PBO and dulaglutide 1.5 mg in 200 patients […]readmore
Shots: Emgality’s approval is based on two P-III trials (N=425) (EVOLVE-1 and EVOLVE-2) and one P-III REGAIN trial (N=450) administering once monthly PBO vs Emgality 120 mg after an initial […]readmore
Shots: Elanco files a registration with U.S. SEC for potential IPO, expected to end by 201 Offering an ownership of <20% shares of Elanco for Lilly The no. of […]readmore
Shots: The extension provides a better understanding to clinicians and initial funding discoveries, molecular analyses, design and conduct of samples for new discoveries in cancer Agreement defines that Dana has […]readmore